Alexandra Haas is a senior associate in Goodwin’s Life Sciences group and a member of the firm’s Intellectual Property Transactions and Strategies practice. She joined Goodwin in 2020. Alexandra is admitted to practice in Massachusetts, the District of Colombia, and Ohio.
Alexandra represents public and private biotechnology, pharmaceutical, diagnostic, medical device, and other life science companies in complex collaboration, co-development, licensing, commercial, M&A, royalty monetization, financing and other intellectual property and strategic transactions.
Experience
- Dren Bio in its sale to Sanofi of its targeted bispecific myeloid cell engager, DR-0201, for an upfront of $600m and potential deal value up to $1.9 billion
- Replicate Bioscience on a multi-year research collaboration with Novo Nordisk for up to $550 million
- Ollin Biosciences in its $100 million launch and collaboration with Innovent Biologics
- bit.bio in its collaboration and option agreement with BlueRock for iPSC-derived regulatory T cells
- Nimbus Therapeutics in its research collaboration and license agreement with a global pharmaceutical company, with deal value of up to $496 million, plus royalties
- QED Therapeutics in its $2.45 billion global collaboration with Helsinn Group to co-develop and commercialize infigratinib for oncology indications
- BridgeBio Pharma in its exclusive license agreement with Bristol Myers Squibb to develop and commercialize BBP-398, a SHP2 inhibitor for oncology, in a deal valued at up to $905 million
- BeOne in its royalty financing with Royalty Pharma for up to $950 million on Amgen’s Imdelltra
- ImmuNext in its royalty financing with Royalty Pharma for $525 million on Sanofi’s Frexalimab
- Heidelberg Pharma in its royalty financing with Healthcare Royalty for up to $115 million on Zircaix
- Anthos Therapeutics in its acquisition by Novartis for up to $3.1 billion
- Blueprint Medicines Corporation in its acquisition by Sanofi for up to $9.5 billion
- Repligen Corporation in its acquisition of 908 Devices
- ImmuNext in its sale of certain pipeline assets to a private company for up to $142 million in milestones and low single digit royalties
- Repligen Corporation in its acquisition of FlexBiosys
- Nimbus in its sale of Nimbus Lakshmi and its Tyk2 inhibitor program to Takeda for $4 billion upfront and up to $2 billion in commercial-related milestone payments
- İş Private Equity in a $39 million funding of a lab at Harvard University
- Moderna in its supply agreements for Moderna’s COVID-19 vaccine with governments around the world
Credentials
Education
JDIntellectual Property and Information2020
Boston University School of Law
BAEconomics and Hispanic Studies2017
Davidson College
Admissions
Bars
- Massachusetts
- Ohio
- District of Columbia
Recognition & Awards
While in law school, Alexandra was awarded the G. Joseph Tauro Distinguished Scholars award and the Edward F. Hennessey Distinguished Scholars and top 15 students award. Alexandra graduated law school eighth in her class.